Fifth Third Bancorp
FITB
$50.37
+0.04%
Fifth Third Bancorp is a Cincinnati-headquartered regional bank with roughly $300 billion in total assets, providing retail and commercial banking, card and treasury management, wealth and asset management, and capital markets services across a Midwest core and an expanding Southeast footprint. The bank sits in the upper tier of U.S. regional banks and has historically differentiated itself through fee-income diversification and its payments and merchant-acquiring capabilities rather than pure spread lending. The dominant investor narrative today is the February 2026 close of the Comerica acquisition, which vaulted Fifth Third into the top-10 U.S. banking ranks and shifted the debate toward integration execution, cost-synergy realization, and the dilution and credit-marking risk that accompany a deal of this size. Attention is also focused on whether the enlarged balance sheet can deliver the promised earnings accretion against a backdrop of a flattening net interest margin and a stock that has round-tripped much of its post-deal enthusiasm.…
FITB
Fifth Third Bancorp
$50.37
Related headlines
FITB 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Fifth Third Bancorp's 12-month outlook, with a consensus price target around $61.71 and implied upside of +22.5% versus the current price.
Average Target
$61.71
0 analysts
Implied Upside
+22.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$55 - $67
Analyst target range
Coverage is robust with 21 analysts and a consensus recommendation of "buy" (mean rating 1.64 on a 1-to-5 scale where 1 is strong buy), and the average target price of $61.71 implies +22.5% upside from the current $50.37. The consensus leans clearly bullish, and the gap between the $61.71 average target and the $50.37 price is unusually wide for a large-cap bank, suggesting analysts view the recent selloff as an overreaction to integration noise rather than a fundamental deterioration. Consensus 2027 EPS of $5.41 and revenue of $14.80 billion underpin that view, and the forward PE of 10.18x versus the target-implied multiple of roughly 11.4x shows the targets assume only modest re-rating, not heroic multiple expansion. The target range of $55.00 to $67.00 is moderately wide — a 21.8% spread from low to high — with even the low target implying +9.2% upside, meaning no covering analyst sees downside from here. The high target of $67.00 (about +33% upside) likely assumes full Comerica cost synergies, net interest margin stabilization, and a re-rating toward 1.6x-1.7x book, while the low target of $55.00 (+9.2%) prices in slower synergy capture and continued margin pressure without a credit event. Institutional ratings show a constructive tilt: Citigroup upgraded to Buy from Neutral on September 22, 2026, Truist reiterated Buy on September 23, and UBS, BofA, DA Davidson, RBC, and JP Morgan all carry Buy/Outperform/Overweight ratings, with only Keefe Bruyette (Market Perform) and Evercore (In Line) sitting on the sidelines. The recent upgrade cadence into late September, even as the stock fell, is a meaningful signal that fundamental analysts see value at these levels; the tight clustering of targets above the current price and the absence of any Sell rating indicate high conviction in the post-merger earnings trajectory.
Drowning in data?
Find the real signal!
Bulls vs Bears: FITB Investment Factors
The bear case currently has stronger near-term evidence: FITB has underperformed SPY by 15.86 points over three months, sits 15% below its 52-week high, and has seen EBITDA margins compress from 29.45% to 23.38% as acquired assets dilute the mix. The bull case rests on a forward-looking bet — a 10.18x forward PE against a $61.71 average target implies analysts see the selloff as an overreaction, and the Q2 rebound to $801 million of net income shows the franchise can earn through integration noise. The single most important tension is whether Comerica cost synergies and NIM stabilization arrive fast enough to validate the 23% implied earnings growth embedded in the forward multiple; if they do, the stock re-rates toward 1.6x-1.7x book, and if they slip, the 1.43x P/B has room to mean-revert toward its 0.99x historical floor.
Bullish
- Analyst consensus sees 22.5% upside: All 21 covering analysts rate FITB a buy (mean 1.64), with an average target of $61.71 versus the $50.37 price — a +22.5% implied return. Even the lowest target of $55.00 implies +9.2% upside, meaning no analyst models downside from here.
- Forward PE of 10.18x is undemanding: The trailing PE of 13.19x collapses to a forward PE of 10.18x on consensus EPS of $5.41, implying the market expects roughly 23% earnings growth as a full year of Comerica contribution and synergies land. That multiple embeds substantial skepticism about integration execution.
- Revenue inflected 37.95% on Comerica: Q2 2026 revenue of $4.431 billion grew 37.95% YoY from $3.212 billion and 14.6% sequentially from Q1's $3.867 billion, a clear step-change from the ~$3.1-3.3 billion pre-deal run-rate. The enlarged balance sheet is delivering top-line scale immediately.
- Profitability rebounded sharply in Q2: Q2 2026 net income of $801 million on an 18.08% net margin and 23.38% operating margin compares with Q1's depressed $165 million and 4.27% net margin, which absorbed $790 million of merger-related other expenses. The swing from $0.16 to $0.84 EPS shows the underlying franchise earning power once deal charges fade.
Bearish
- Three-month relative strength of -15.86: FITB fell 13.17% over three months while SPY rose 2.69%, producing relative strength of -15.86 — the most severe reading in the dataset. With a beta of 0.986, this underperformance is almost entirely idiosyncratic, pointing to active de-rating on integration and margin concerns rather than market drag.
- EBITDA margin compressed to 23.38%: The EBITDA margin fell from 29.45% in Q2 2025 to 23.38% in Q2 2026 even as revenue grew 37.95%, as lower-margin acquired Comerica assets and integration costs diluted the mix. Gross margin also slipped from 70.98% in Q2 to 65.29% on a TTM basis.
- P/B near top of five-year range: At 1.43x book, FITB sits near the upper end of a historical band that ran from roughly 0.99x in Q1 2023 to 1.49x in Q2 2026. The stock has de-rated from 1.49x to 1.43x and trailing PE from 16.78x to 13.19x, but it is not a deep-value proposition on its own history.
- Earnings quality is acquired, not organic: The revenue step-change is deal-driven, and segment disclosure shows Commercial Banking at $220 million and Branch Banking at $160 million dominating while Wealth and Asset Management contributes only $2 million. The franchise remains a spread-and-commercial-lending story, so NIM compression directly threatens the accretion thesis.
FITB Technical Analysis
Fifth Third is in a medium-term uptrend that has stalled into a corrective phase: the stock is up 24.80% over the trailing year versus a 15.53% gain for SPY, yet it sits at $50.37, only 32.3% of the way through its 52-week range of $40.66 to $59.50. That positioning — a strong 12-month record but a price more than 15% below the 52-week high — is characteristic of a momentum name that has lost sponsorship rather than a value opportunity at the lows, and the 21.21% maximum drawdown confirms meaningful peak-to-trough damage. The 6-month change of +0.06% versus SPY's +7.48% (relative strength of -7.42) shows the stock has been dead money for two quarters even as the broader market advanced. Recent momentum is clearly negative and diverging from the longer-term trend: the 1-month change of -3.89% and 3-month change of -13.17% compare with SPY at +1.22% and +2.69%, producing relative strength of -5.11 and -15.86 over those windows. The 3-month underperformance is the most severe reading in the dataset and signals active de-rating — likely post-deal integration concerns and margin pressure — rather than a benign pullback; the 1-month decline is shallower than the 3-month, hinting at decelerating downside but not yet a reversal. The stock's beta of 0.986 means it moves roughly in line with the market, so the -13.17% three-month move is largely idiosyncratic and cannot be dismissed as market beta. Key levels are well defined: support sits at the $40.66 52-week low, roughly 19% below the current price, while resistance is the $59.50 52-week high, about 18% above; a decisive break above $59.50 would confirm the post-merger re-rating thesis and likely trigger momentum buying, whereas a break of $40.66 would signal that the market is pricing in credit deterioration or synergy failure. The short ratio of 6.14 days-to-cover indicates moderate but not extreme bearish positioning, and with average volume of 6.46 million shares, liquidity is ample for institutional repositioning.
Beta
0.99
0.99x market volatility
Max Drawdown
-21.2%
Largest decline past year
52-Week Range
$41-$60
Price range past year
Annual Return
+24.8%
Cumulative gain past year
| Period | FITB Return | S&P 500 |
|---|---|---|
| 1m | -3.9% | +0.2% |
| 3m | -13.2% | +2.9% |
| 6m | +0.1% | +8.4% |
| 1y | +24.8% | +14.9% |
| ytd | +5.6% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
FITB Fundamental Analysis
Revenue has inflected sharply upward on the Comerica consolidation: Q2 2026 revenue of $4.431 billion grew 37.95% year over year versus $3.212 billion in Q2 2025, and rose 14.6% sequentially from Q1 2026's $3.867 billion. The multi-quarter arc shows $3.075 billion in Q1 2025, $3.212 billion in Q2 2025, $3.300 billion in Q3 2025, $3.279 billion in Q4 2025, then a step-change to $3.867 billion and $4.431 billion in the first two quarters of 2026 — the deal closed in February 2026 and the Q1 print captured only partial contribution. Segment disclosure is thin, but Commercial Banking at $220 million and Branch Banking at $160 million dominate reported segment values while Wealth and Asset Management contributes only $2 million, underscoring that the franchise remains a spread-and-commercial-lending story rather than a fee-compounding platform. The growth trend strongly supports the investment case on a top-line basis, but the quality of that growth — acquired versus organic — is the central question for investors. Profitability is solid but lumpy: Q2 2026 net income was $801 million on a 70.98% gross margin and 18.08% net margin, a dramatic rebound from Q1 2026's $165 million and 4.27% net margin, which was depressed by merger-related charges and a $790 million other-expense line. Q2 2026 operating margin of 23.38% and EBITDA of $1.036 billion compare favorably with the pre-deal run-rate (Q2 2025 EBITDA of $946 million on a 29.45% EBITDA margin), though the EBITDA margin has compressed from 29.45% to 23.38% as lower-margin acquired assets and integration costs dilute the mix. The Q1-to-Q2 swing in EPS from $0.16 to $0.84 (diluted $0.15 to $0.83) illustrates how noisy the reported numbers are during integration; the trailing EPS of $0.081 in the key metrics file appears to be a distorted or partial-period figure and should not be relied upon, whereas the $5.41 consensus forward EPS is the more meaningful earnings anchor. Balance sheet and cash flow metrics are healthy for a regional bank: debt-to-equity of 0.668, ROE of 11.61%, ROA of 0.92%, and TTM free cash flow of $3.491 billion against a $31.1 billion market cap imply a free cash flow yield of roughly 11.2%. Q2 2026 operating cash flow of $2.796 billion and FCF of $2.622 billion were strong, though Q1 2026 operating cash flow was -$1.106 billion and FCF -$1.252 billion, reflecting working-capital and securities-repositioning swings around the deal. Dividends of $402 million in Q2 are comfortably covered by operating cash flow, and the 0.668 debt-to-equity ratio leaves room for further balance-sheet integration without external capital dependence.
Quarterly Revenue
$4.4B
2026-06
Revenue YoY Growth
+38.0%
YoY Comparison
Gross Margin
71.0%
Latest Quarter
Free Cash Flow
$3.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is FITB Overvalued?
Because Fifth Third is profitable — Q2 2026 net income of $801 million and positive trailing earnings — the PE ratio is the appropriate primary metric, and the trailing PE of 13.19x against a forward PE of 10.18x implies the market expects roughly 23% earnings growth over the next twelve months, consistent with a full year of Comerica contribution and synergy capture. The forward multiple of 10.18x on consensus EPS of $5.41 is undemanding in absolute terms and reflects skepticism that the accretion will materialize on schedule. On the bank-appropriate price-to-book metric, FITB trades at 1.43x book versus a historical band that has ranged from roughly 0.99x (Q1 2023) to 1.49x (Q2 2026), placing it near the upper end of its own five-year range despite the recent price decline. Peer comparison is constrained by the absence of an explicit industry-average multiple in the valuation dataset, but the 1.43x P/B and 13.19x trailing PE are broadly in line with large regional bank norms and well below money-center valuations, suggesting the stock is not expensive relative to the sector; the 2.42x PS ratio and 6.35x EV/Sales look elevated only because bank revenue is not the right denominator for enterprise value. The PEG ratio of 1.07 is close to fair value, and the 3.74% dividend yield with a 46.1% payout ratio provides a meaningful income cushion. Historical context is instructive: the trailing PE has compressed from 16.78x in Q2 2026 to 13.19x now, and the P/B has drifted from 1.49x to 1.43x, meaning the stock has de-rated even as book value grew — the market is pricing in integration risk and margin compression rather than assigning a premium for scale. The current 1.43x P/B sits in the top quartile of the historical range shown (which bottomed near 0.99x in early 2023), so the stock is not a deep-value proposition on its own history; the case rests on forward EPS delivery closing the gap between the 13.19x trailing and 10.18x forward multiples.
PE
13.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 7x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risk centers on integration execution and earnings quality. Q1 2026 net income collapsed to $165 million (4.27% net margin) on a $790 million other-expense line, and the Q1-to-Q2 EPS swing from $0.16 to $0.84 shows how volatile reported results are during the Comerica integration. The EBITDA margin has compressed from 29.45% to 23.38% YoY despite 37.95% revenue growth, meaning the acquired book is lower-margin and synergy capture is not yet visible in the numbers. Revenue concentration is also a concern: Commercial Banking ($220 million) and Branch Banking ($160 million) dominate segment disclosure while Wealth and Asset Management contributes only $2 million, leaving the franchise heavily exposed to net interest margin and commercial credit rather than diversified fee income. The 0.668 debt-to-equity and 11.61% ROE are healthy, but a $300 billion balance sheet with freshly marked Comerica credit carries unquantified reserve risk.
Market and competitive risk is dominated by valuation compression and sector rotation. At 1.43x book, FITB trades near the top of its five-year range (0.99x-1.49x), so there is limited multiple cushion if regional bank sentiment sours; the trailing PE has already compressed from 16.78x to 13.19x, and further de-rating would compound any earnings disappointment. The beta of 0.986 means the stock offers essentially no defensive offset in a market selloff, and the -13.17% three-month move against SPY's +2.69% confirms the recent damage is idiosyncratic — the market is actively repricing FITB-specific integration and margin risk, not just rotating out of banks. Competitive pressure from money-center banks and fintechs in the Southeast expansion markets adds a structural headwind, and the 6.14 short ratio indicates bears have built a meaningful position that could accelerate declines on a negative headline.
The worst-case scenario is a synergy shortfall combined with commercial credit deterioration: if Comerica cost savings slip past 2027 and a credit event forces reserve builds, the forward EPS of $5.41 would be cut and the 10.18x multiple would compress simultaneously — a classic double hit. In that chain, the stock would retest its 52-week low of $40.66, roughly 19% below the current $50.37, and a break of that level would signal the market is pricing synergy failure or credit losses. The 21.21% max drawdown already realized shows the magnitude of damage this name can absorb; a realistic adverse case is -19% to the 52-week low, with a tail scenario toward the 0.99x book multiple implying a deeper decline if book value itself is impaired by credit marks.